Welcome to LookChem.com Sign In|Join Free
  • or
4-benzyl-[1,2,4]triazolo[4,3-a]quinoxaline is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1252995-53-1

Post Buying Request

1252995-53-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1252995-53-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1252995-53-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,2,9,9 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1252995-53:
(9*1)+(8*2)+(7*5)+(6*2)+(5*9)+(4*9)+(3*5)+(2*5)+(1*3)=181
181 % 10 = 1
So 1252995-53-1 is a valid CAS Registry Number.

1252995-53-1Downstream Products

1252995-53-1Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel 1,2,4-triazolo and 1,2,4-triazino[4,3-a]quinoxalines as potential anticancer and antimicrobial agents

Issa, Doaa A. E.,Habib, Nargues S.,Abdel Wahab, Abeer E.

, p. 202 - 211 (2015)

In an effort to find new leads as anticancer or antimicrobial agents, the present work deals with the synthesis of some novel 1-substituted 1,2,4-triazolo[4,3-a]quinoxalines 7, 9a,b, and 14-19 and 1,2,4-triazino[4,3-a]quinoxalines 10a-c as well as 2-[5-amino-3-(4-chlorophenyl)pyrazol-1-yl]-3-benzylquinoxaline 13. These were synthesized using the key intermediate 3-benzyl-2-hydrazinoquinoxaline 6 with various reagents. Ten compounds, namely 7, 9a, 10b, 11, and 13-18 were chosen by the National Cancer Institute of Bethesda (NCI) for evaluation of their anticancer activity. The results indicated that 9a was the most active and was further evaluated for in vitro five dose assay against 60 human cell lines. It was proven to possess the highest broad spectrum anticancer activity. It showed particular effectiveness towards leukemia SR, non-small cell lung cancer HOP-92, NCI-H460, colon cancer HCT-116, HCT-15, CNS cancer U251, melanoma LOX IMVI, renal cancer A498, prostate cancer PC-3, and breast cancer MDA-MB-468 cell lines (GI50 = 3.91, 3.45, 3.49, 3.21, 1.96, 5.18, 3.69, 1.80, 5.19, and 5.55 μM, respectively). All new compounds were screened for their antimicrobial activity and were very active against P. aeruginosa. Compounds 10a and 16 were twice as active as ampicillin against P. aeruginosa. Five compounds, 9a, b, 10b, 13, and 14 were equipotent to ampicillin against P. aeruginosa. In addition, compound 16 showed a broad spectrum antimicrobial activity. Furthermore, compound 9a showed dual activity as an anticancer and antimicrobial agent. This journal is

Synthesis of new series of quinoxaline based MAO-inhibitors and docking studies

Khattab, Sherine N.,Hassan, Seham Y.,Bekhit, Adnan A.,El Massry, Abdel Moneim,Langer, Vratislav,Amer, Adel

experimental part, p. 4479 - 4489 (2010/10/19)

A series of 2-benzyl-3-(2-arylidenehydrazinyl)quinoxalines 3, 4-benzyl-1-aryl-[1,2,4]triazolo[4,3-a]quinoxalines 4 and phenyl(1-aryl-[1,2,4] triazolo[4,3-a]quinoxalin-4-yl)methanones 5 analogues were synthesized and investigated for their monoamine oxidas

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1252995-53-1